市場調査レポート
商品コード
1303610

分子診断の世界市場:製品・サービス別 (試薬、キット)・検査の種類別 (検査室、PoC)・サンプルの種類別 (血液、尿)・技術別 (PCR、INAAT)・用途別 (感染症、腫瘍)・エンドユーザー別 (診断検査室、病院)・地域別の将来予測 (2028年まで)

Molecular Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample Type (Blood, Urine), Technology (PCR, INAAT), Application (Infectious, Oncology), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 310 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.54円
分子診断の世界市場:製品・サービス別 (試薬、キット)・検査の種類別 (検査室、PoC)・サンプルの種類別 (血液、尿)・技術別 (PCR、INAAT)・用途別 (感染症、腫瘍)・エンドユーザー別 (診断検査室、病院)・地域別の将来予測 (2028年まで)
出版日: 2023年07月03日
発行: MarketsandMarkets
ページ情報: 英文 310 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の分子診断の市場規模は、2023年に166億米ドル、2028年には286億米ドルに達し、11.4%のCAGRで成長すると予測されます。

結核、HIV/AIDS、肝炎、性感染症、呼吸器感染症などの疾患は、効果的な治療と管理のために正確でタイムリーな診断を必要とします。分子診断はこれらの感染症の検出とモニタリングにおいて重要な役割を果たしており、この分野の市場成長を牽引しています。

感染症診断とは別に、分子診断技術は、特にがんの分野において、患者管理を強化するためにますます使用されるようになってきています。世界のがん罹患率の増加は検査検体数を増加させるため、分子診断法を含む新たな診断法に対する需要を生み出しています。

"サンプルの種類別では予測期間中、血液・血清・血漿のセグメントが最も高い成長率で成長する"

分子診断における血液・血清・血漿セグメントは、感染症検査の需要増に大きく牽引され、大幅な成長を遂げています。感染症は世界的に重大な健康問題を引き起こしており、これらの疾患を正確かつタイムリーに診断することは、効果的な疾病管理と公衆衛生対策にとって極めて重要です。

血漿・血清サンプルは、感染症検査にいくつかの利点を提供します。血漿・血清サンプルは、ウイルス感染、細菌感染、真菌感染、寄生虫感染などの感染症において、幅広い診断用途があります。これらは早期診断、適切な治療法の選択、治療効果の評価に役立ちます。さらに、血液ベースの分子診断は、遺伝子検査、感染症診断、がん診断、疾患進行のモニタリングなど、幅広い用途で臨床的有用性を実証しています。

"用途別では予測期間中、がん検査セグメントが成長率が最も高い"

がん治療における精密医療と個別化アプローチの重要性が高まっていることを反映して、がん検査分野は現在、分子診断薬市場の中で最も高い成長率を示しています。オンコロジー検査に対する需要の急増は、がんの診断と治療の展望を変えつつある様々な要因に後押しされています。分子診断検査によって、医師は遺伝物質の病気に対する素因を調べ、がんなどの病気を早期に診断することができます。

様々な戦略的展開を通じて、製薬会社と分子診断薬メーカーは、個別化医療とコンパニオン診断アッセイを開発し、所定の薬物療法に対する患者の反応モニタリングをサポートするために、その相乗効果を統合することにますます注力しています。これが腫瘍検査分野の成長を後押しする主な要因です。このセグメントの成長は、技術の進歩やがんの罹患率の増加によっても牽引されています。

"アジア太平洋:最も急成長している地域の分子診断薬市場"

アジア太平洋は予測期間中に最も高いCAGRを記録すると予測されています。この地域の新興国はGDPの成長と可処分所得水準の大幅な上昇を目の当たりにしています。このため、アジア太平洋諸国では、巨大な人口に伴う医療費の増加、医療インフラの近代化、最先端の臨床検査技術の浸透が進んでいます。これらの要因は、この地域で事業を展開する分子診断薬企業に大きな成長機会をもたらすと期待されています。

メディカルツーリズムのハブとなっているアジア太平洋は、医療処置や医療機器の最も急成長している市場のひとつと考えられています。低いインフラと治療費、高度な教育を受けた医師がいることが、メディカルツーリストをこれらの国々に向かわせる原動力となっており、これがこの地域の分子診断薬市場の成長を促す大きな要因となっています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 価格分析
  • 特許分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム/市場マップ分析
  • ポーターのファイブフォース分析
  • 規制分析
  • 貿易分析
  • 技術分析
  • 主な会議とイベント (2023年~2024年)
  • PESTLE分析
  • 顧客のビジネスに影響を与える動向/混乱
  • 主要な利害関係者と購入基準
  • ケーススタディ分析

第6章 分子診断市場:製品・サービス別

  • イントロダクション
  • 試薬・キット
  • 装置
  • サービス・ソフトウェア

第7章 分子診断市場:検査の種類別

  • イントロダクション
  • 検査室検査
  • PoC検査

第8章 分子診断市場:サンプルの種類別

  • イントロダクション
  • 血液・血清・血漿
  • 尿
  • その他の種類のサンプル

第9章 分子診断市場:技術別

  • イントロダクション
  • ポリメラーゼ連鎖反応 (PCR)
  • 等温核酸増幅技術 (INAAT)
  • DNAシーケンスと次世代シーケンス
  • in situハイブリダイゼーション
  • DNAマイクロアレイ
  • その他の技術

第10章 分子診断市場:用途別

  • イントロダクション
  • 感染症診断
    • 肝炎
    • HIV
    • CT/NG
    • 医療関連感染 (HAI)
    • HPV
    • 結核
    • インフルエンザ
    • その他の感染症
  • 腫瘍検査
    • 乳がん
    • 結腸直腸がん
    • 肺がん
    • 前立腺がん
    • その他のがん
  • 遺伝子検査
  • その他の用途
  • COVID-19

第11章 分子診断市場:エンドユーザー別

  • イントロダクション
  • 診断検査室
  • 病院・診療所
  • その他のエンドユーザー

第12章 地域別の分子診断市場

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • ロシア
    • その他の欧州
  • アジア太平洋
    • 日本
    • インド
    • オーストラリア
    • その他のアジア太平洋
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ
  • 中東・アフリカ

第13章 競合情勢

  • 概要
  • 主要企業が採用した戦略
  • 上位企業の収益シェア分析
  • 市場シェア分析
  • 主要企業の企業評価マトリックス
  • スタートアップ/中小企業の企業評価マトリックス (2022年)
  • 競合ベンチマーキング
  • 競合シナリオ

第14章 企業プロファイル

  • 主要企業
    • F. HOFFMANN-LA ROCHE LTD.
    • HOLOGIC, INC.
    • ABBOTT LABORATORIES
    • BIOMERIEUX
    • THERMO FISHER SCIENTIFIC INC.
    • QIAGEN
    • PERKINELMER INC.
    • MYRIAD GENETICS, INC.
    • SIEMENS HEALTHINEERS AG
    • DANAHER
  • その他の企業
    • ILLUMINA, INC.
    • BECTON, DICKINSON AND COMPANY
    • GRIFOLS, S.A.
    • QUIDELORTHO CORPORATION
    • AGILENT TECHNOLOGIES, INC.
    • DIASORIN S.P.A.
    • EXACT SCIENCES CORPORATION
    • GENETIC SIGNATURES
    • MDXHEALTH
    • HTG MOLECULAR DIAGNOSTICS, INC.
    • BIOCARTIS
    • TBG DIAGNOSTICS LIMITED
    • VELA DIAGNOSTICS
    • AMOY DIAGNOSTICS CO., LTD.
    • ELITECHGROUP
    • MOLBIO DIAGNOSTICS PVT. LTD.
    • SAVYON DIAGNOSTICS
    • ABACUS DIAGNOSTICA OY
    • GENEOMBIO TECHNOLOGIES PVT. LTD.

第15章 付録

目次
Product Code: MD 2521

The molecular diagnostics market is valued at an estimated USD 16.6 billion in 2023 and is projected to reach USD 28.6 billion by 2028 at a CAGR of 11.4% during the forecast period. Diseases such as tuberculosis, HIV/AIDS, hepatitis, sexually transmitted infections, and respiratory infections require an accurate and timely diagnosis for effective treatment and control. Molecular diagnostics play a crucial role in the detection and monitoring of these infectious diseases, driving the growth of the market in this area.

Apart from infectious disease diagnostics, molecular diagnostic techniques are increasingly being used to enhance patient management, particularly in the field of cancer. The growing prevalence of cancer globally will increase the number of specimens tested, thus creating a demand for new diagnostic procedures, including molecular diagnostics.

"Blood, serum, and plasma segment accounted for the highest growth rate in the molecular diagnostics market, by sample type, during the forecast period"

The molecular diagnostics market is bifurcated into blood, serum, and plasma, urine, and other sample types on the basis of sample type. The blood, serum, and plasma segment in molecular diagnostics is experiencing substantial growth, largely driven by the increased demand for infectious disease testing. Infectious diseases pose significant global health challenges, and the accurate and timely diagnosis of these conditions is crucial for effective disease management and public health measures.

Plasma and serum samples provide several advantages for infectious disease testing. Plasma and serum samples have wide-ranging diagnostic applications in infectious diseases, including viral, bacterial, fungal, and parasitic infections. They aid in early diagnosis, appropriate treatment selection, and the assessment of treatment response. Moreover, Blood-based molecular diagnostics have demonstrated clinical utility across a broad range of applications, including genetic testing, infectious disease diagnosis, cancer diagnostics, and monitoring disease progression.

"Oncology testing segment accounted for the highest growth rate in the molecular diagnostics market, by application, during the forecast period"

The global molecular diagnostics market is bifurcated into infectious disease diagnostics, oncology testing, genetic testing, and other applications. Oncology testing segment is currently witnessing the highest growth rate within the molecular diagnostics market, reflecting the increasing importance of precision medicine and personalized approaches in cancer care. The surge in demand for oncology testing is fueled by various factors that are transforming the landscape of cancer diagnostics and treatment. Molecular diagnostic tests enable physicians to study the predisposition of genetic materials to diseases and diagnose diseases, such as cancer, at an early stage.

Through various strategic developments, pharmaceutical companies and molecular diagnostic manufacturers have increasingly focused on integrating their synergies to develop personalized medicine and companion diagnostic assays that can support the monitoring of a patient's response to a given drug therapy. This is a major factor boosting the growth of the oncology testing segment. The growth of this segment is also driven by technological advancements and the increasing incidence of cancer.

"Asia Pacific: The fastest-growing region molecular diagnostics market"

The global molecular diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in this region have witnessed growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies in the Asia Pacific countries. These factors are expected to provide significant growth opportunities for molecular diagnostic companies operating in this region.

The Asia Pacific, which has become a medical tourism hub, is considered one of the fastest-growing markets for medical procedures and devices. Low infrastructure and treatment costs and the availability of highly educated physicians have driven medical tourists to these countries, which is a major factor driving the growth of the molecular diagnostics market in this region.

The break-up of the profile of primary participants in the molecular diagnostics market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), bioMerieux (France), QIAGEN (Netherlands), PerkinElmer Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Danaher (US), Illumina, Inc. (US), Becton, Dickinson and Company (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), Agilent Technologies, Inc. (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), MDx Health (Belgium), Biocartis (Belgium), TBG Diagnostics Limited (Australia), HTG Molecular Diagnostics, Inc. (US), Vela Diagnostics (Singapore), Amoy Diagnostics Co., Ltd. (China), ELITechGroup (France), Molbio Diagnostics Pvt. Ltd. (India), Savyon Diagnostics (Israel), Abacus Diagnostica Oy (Finland), and geneOmbio Technologies Pvt. Ltd. (India).

Research Coverage:

This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services & software), test type (lab tests and PoC tests), sample type (blood, serum, and plasma, urine, and other sample types), application (infectious disease diagnostics (hepatitis, HIV, CT/NG, HAI, HPV, tuberculosis, influenza, and other infectious diseases), oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancer testing), genetic testing, and other applications, technology (polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, in situ hybridization, DNA microarrays, and other technologies), end user (diagnostic laboratories, hospitals & clinics, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the molecular diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product & service launches, and recent developments associated with the molecular diagnostics market. Competitive analysis of upcoming startups in the molecular diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (increasing prevalence of infectious diseases and cancer globally, rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies, growing awareness of early disease diagnosis in developing countries, rising technological advancements in molecular diagnostics in recent years, and increasing use of PoC diagnostic tests in homecare settings and hospitals), restraints (unfavorable reimbursement scenario for diagnostic companies and high cost of molecular diagnostic instruments), opportunities (growing significance of companion diagnostics in drug development process and growth opportunities for molecular diagnostic companies in emerging economies), and challenges (changing regulatory landscape for IVD and molecular diagnostics in US and European Union, operational barriers and shortage of skills across major markets, and introduction of alternative technologies for disease detection and diagnosis) influencing the growth of the molecular diagnostics market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular diagnostics market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the molecular diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the molecular diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), and bioMerieux (France), among others in the molecular diagnostics market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MOLECULAR DIAGNOSTICS MARKET: MARKET SEGMENTATION
    • 1.3.2 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL SEGMENTATION
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 MARKET LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Company presentations and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 6 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
  • 2.8 GROWTH RATE ASSUMPTIONS
  • 2.9 RISK ASSESSMENT
    • 2.9.1 RISK ASSESSMENT OF MOLECULAR DIAGNOSTICS MARKET
  • 2.10 IMPACT OF ECONOMIC RECESSION ON MOLECULAR DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 8 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 9 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 15 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND RISING INCIDENCE OF CANCER TO SUPPORT MARKET
  • 4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
    • FIGURE 16 REAGENTS & KITS TO DOMINATE MOLECULAR DIAGNOSTICS MARKET IN 2028
  • 4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2028
    • FIGURE 17 LAB TESTS TO COMMAND GREATER MARKET SHARE IN 2028
  • 4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023 VS. 2028
    • FIGURE 18 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
  • 4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028
    • FIGURE 19 PCR SEGMENT TO DOMINATE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD
  • 4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028
    • FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2028
  • 4.7 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028
    • FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.8 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
    • FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MOLECULAR DIAGNOSTICS MARKET DURING STUDY PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 23 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of infectious diseases and cancer globally
    • TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
    • TABLE 2 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
      • 5.2.1.2 Rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies
      • 5.2.1.3 Growing awareness regarding early disease diagnosis in developing countries
      • 5.2.1.4 Rising technological advancements in molecular diagnostics in recent years
      • 5.2.1.5 Increasing use of PoC diagnostic tests in homecare settings and hospitals
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
      • 5.2.2.2 High cost of molecular diagnostic instruments
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing significance of companion diagnostics in drug development process
      • 5.2.3.2 Increasing growth opportunities for molecular diagnostics companies in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Changing regulatory landscape for IVD and molecular diagnostics in US and European Union
      • 5.2.4.2 Operational barriers and shortage of skills across major markets
      • 5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
  • 5.3 PRICING ANALYSIS
    • 5.3.1 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS PRODUCTS, BY KEY PLAYER
    • TABLE 3 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS
  • 5.4 PATENT ANALYSIS
    • FIGURE 24 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013-DECEMBER 2022)
    • 5.4.1 LIST OF MAJOR PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 25 VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 26 MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM/MARKET MAP ANALYSIS
    • FIGURE 27 MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM/MARKET MAP ANALYSIS
    • 5.7.1 MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 4 MOLECULAR DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT FROM NEW ENTRANTS
    • 5.8.2 THREAT FROM SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY ANALYSIS
    • TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.9.1 NORTH AMERICA
      • 5.9.1.1 US
      • 5.9.1.2 Canada
    • 5.9.2 EUROPE
    • TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 China
      • 5.9.3.2 Japan
    • TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.9.3.3 India
    • 5.9.4 LATIN AMERICA
      • 5.9.4.1 Brazil
      • 5.9.4.2 Mexico
    • 5.9.5 MIDDLE EAST
    • 5.9.6 AFRICA
  • 5.10 TRADE ANALYSIS
    • 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
      • 5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
      • 5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
  • 5.11 TECHNOLOGY ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
    • TABLE 11 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023-2024
  • 5.13 PESTLE ANALYSIS
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 5.14.1 REVENUE SHIFT IN MOLECULAR DIAGNOSTICS MARKET
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS
    • TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MOLECULAR DIAGNOSTIC PRODUCTS (%)
    • 5.15.2 BUYING CRITERIA
    • FIGURE 29 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
    • TABLE 13 KEY BUYING CRITERIA FOR MOLECULAR DIAGNOSTIC PRODUCTS
  • 5.16 CASE STUDY ANALYSIS
    • FIGURE 30 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 14 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 15 PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS (2022)
  • 6.2 REAGENTS & KITS
    • 6.2.1 RECURRENT PURCHASES OF REAGENTS & KITS FOR DIAGNOSTIC ANALYSIS TO PROPEL MARKET
    • TABLE 16 MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
    • TABLE 17 KEY INSTRUMENTS AVAILABLE IN GLOBAL MARKET
    • TABLE 18 MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 SERVICES & SOFTWARE
    • 6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET TO DRIVE GROWTH
    • TABLE 19 MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2021-2028 (USD MILLION)

7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE

  • 7.1 INTRODUCTION
    • TABLE 20 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2028 (USD MILLION)
    • 7.1.1 PRIMARY NOTES
      • 7.1.1.1 Key industry insights
  • 7.2 LAB TESTS
    • 7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
    • TABLE 21 MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 POC TESTS
    • 7.3.1 FASTER TURNAROUND TIME OF POC TESTS TO DRIVE SEGMENT GROWTH
    • TABLE 22 MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021-2028 (USD MILLION)

8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

  • 8.1 INTRODUCTION
    • TABLE 23 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • 8.2 BLOOD, SERUM, AND PLASMA
    • 8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
    • TABLE 24 MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 URINE
    • 8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
    • TABLE 25 MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 OTHER SAMPLE TYPES
    • TABLE 26 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021-2028 (USD MILLION)

9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 9.1 INTRODUCTION
    • 9.1.1 PRIMARY NOTES
      • 9.1.1.1 Key industry insights
    • TABLE 27 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 9.2 POLYMERASE CHAIN REACTION
    • 9.2.1 GROWING USE OF POLYMERASE CHAIN REACTION IN PROTEOMICS AND GENOMICS TO DRIVE MARKET
    • TABLE 28 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    • 9.3.1 COST BENEFITS OF ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY IN NUCLEIC ACID SEQUENCING TO DRIVE MARKET
    • TABLE 29 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
    • 9.4.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
    • TABLE 30 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
  • 9.5 IN SITU HYBRIDIZATION
    • 9.5.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
    • TABLE 31 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
  • 9.6 DNA MICROARRAYS
    • 9.6.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
    • TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021-2028 (USD MILLION)
  • 9.7 OTHER TECHNOLOGIES
    • TABLE 33 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
    • TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 10.2 INFECTIOUS DISEASE DIAGNOSTICS
    • TABLE 35 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 36 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • 10.2.1 HEPATITIS
      • 10.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive segment
    • TABLE 37 HEPATITIS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 38 HEPATITIS MARKET, BY REGION, 2021-2028 (MILLION TESTS)
    • 10.2.2 HIV
      • 10.2.2.1 Increased global prevalence of HIV to propel segment
    • TABLE 39 HIV MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 40 HIV MARKET, BY REGION, 2021-2028 (MILLION TESTS)
    • 10.2.3 CT/NG
      • 10.2.3.1 CT/NG infections to be most common sexually transmitted disease globally
    • TABLE 41 CT/NG MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 42 CT/NG MARKET, BY REGION, 2021-2028 (MILLION TESTS)
    • 10.2.4 HAIS
      • 10.2.4.1 Rising burden of MRSA infections and increasing adoption of technologically advanced HAI diagnostic tests to aid market
    • TABLE 43 HAIS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 44 HAIS MARKET, BY REGION, 2021-2028 (MILLION TESTS)
    • 10.2.5 HPV
      • 10.2.5.1 Technological advancements for preventing HPV infections to augment market
    • TABLE 45 HPV MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 46 HPV MARKET, BY REGION, 2021-2028 (MILLION TESTS)
    • 10.2.6 TUBERCULOSIS
      • 10.2.6.1 Increasing burden of TB globally to propel market
    • TABLE 47 TUBERCULOSIS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 48 TUBERCULOSIS MARKET, BY REGION, 2021-2028 (MILLION TESTS)
    • 10.2.7 INFLUENZA
      • 10.2.7.1 Rising focus on decreasing spread of influenza to propel segment
    • TABLE 49 INFLUENZA MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 50 INFLUENZA MARKET, BY REGION, 2021-2028 (MILLION TESTS)
    • 10.2.8 OTHER INFECTIOUS DISEASES
    • TABLE 51 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.3 ONCOLOGY TESTING
    • TABLE 52 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 53 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2021-2028 (USD MILLION)
    • 10.3.1 BREAST CANCER
      • 10.3.1.1 Increasing prevalence of breast cancer among females to boost market
    • TABLE 54 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 55 BREAST CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 10.3.2 COLORECTAL CANCER
      • 10.3.2.1 Rising focus on development of companion diagnostic assays to fuel market
    • TABLE 56 COLORECTAL CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 10.3.3 LUNG CANCER
      • 10.3.3.1 Increasing research for lung cancer biomarkers to drive market
    • TABLE 57 LUNG CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 10.3.4 PROSTATE CANCER
      • 10.3.4.1 Advancements in genomic technologies for development of new biomarkers to aid market
    • TABLE 58 PROSTATE CANCER MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 10.3.5 OTHER CANCERS
    • TABLE 59 GLOBAL CANCER INCIDENCE, 2020
    • TABLE 60 OTHER CANCERS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.4 GENETIC TESTING
    • 10.4.1 DIAGNOSIS OF VARIOUS DISEASES THROUGH GENETIC TESTING METHODS TO PROPEL MARKET
    • TABLE 61 MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021-2028 (USD MILLION)
  • 10.5 OTHER APPLICATIONS
    • TABLE 62 MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
  • 10.6 COVID-19
    • 10.6.1 DECLINING CASES OF COVID-19 TO HINDER MARKET
    • TABLE 63 MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021-2028 (USD MILLION)

11 MOLECULAR DIAGNOSTICS MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 64 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2 DIAGNOSTIC LABORATORIES
    • 11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
    • TABLE 65 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
  • 11.3 HOSPITALS & CLINICS
    • 11.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
    • TABLE 66 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2028 (USD MILLION)
  • 11.4 OTHER END USERS
    • TABLE 67 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

12 MOLECULAR DIAGNOSTICS MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 68 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 12.2 NORTH AMERICA
    • FIGURE 31 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 69 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 71 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 72 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 73 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 74 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 75 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 76 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
    • TABLE 77 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 78 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 79 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 80 US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 81 US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 82 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.3 CANADA
      • 12.2.3.1 High availability of funding for genomics research to fuel market
    • TABLE 83 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 84 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 85 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 86 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 88 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.3 EUROPE
    • TABLE 89 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 91 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 92 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 93 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 94 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 95 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 96 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 Increasing healthcare expenditure with favorable government policies and rising per capita disposable income to propel market
    • TABLE 97 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 98 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 99 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 100 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 101 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.3 UK
      • 12.3.3.1 Growing number of accredited diagnostic laboratories to fuel market
    • TABLE 103 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 104 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 105 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 106 UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 107 UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.4 FRANCE
      • 12.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
    • TABLE 109 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 110 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 111 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 112 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 113 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 114 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.5 ITALY
      • 12.3.5.1 Adoption of advanced diagnostic technologies to support market
    • TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 116 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 117 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 118 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 119 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 120 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.6 SPAIN
      • 12.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
    • TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 122 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 123 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 124 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 125 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 126 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.7 RUSSIA
      • 12.3.7.1 Increasing access to quality healthcare and growing incidence of infectious diseases to aid market
    • TABLE 127 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 128 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 129 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 130 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 131 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 132 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.8 REST OF EUROPE
    • TABLE 133 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 134 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 135 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 136 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 137 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 138 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.4 ASIA PACIFIC
    • FIGURE 32 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 139 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 140 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 141 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 142 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 143 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 144 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 145 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
    • 12.4.2 CHINA
      • 12.4.2.1 Rapid economic growth and greater public access to modern healthcare to drive market
    • TABLE 147 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 148 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 149 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 150 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 151 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 152 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.3 JAPAN
      • 12.4.3.1 Universal healthcare reimbursement policy to support market
    • TABLE 153 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 154 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 155 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 156 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 157 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 158 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.4 INDIA
      • 12.4.4.1 Increased private & public investments and large patient population to drive market
    • TABLE 159 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 160 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 161 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 162 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 163 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 164 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.5 AUSTRALIA
      • 12.4.5.1 High prevalence of infectious diseases to fuel market
    • TABLE 165 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 166 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 167 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 168 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 169 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 170 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.6 REST OF ASIA PACIFIC
    • TABLE 171 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 172 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 173 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 174 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 175 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 176 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.5 LATIN AMERICA
    • TABLE 177 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 178 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 179 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 180 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 181 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 182 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 183 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 184 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.5.1 IMPACT OF ECONOMIC RECESSION ON LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market
    • TABLE 185 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 186 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 187 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 188 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 189 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 190 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.5.3 MEXICO
      • 12.5.3.1 Improving accessibility and affordability of healthcare services to aid market
    • TABLE 191 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 192 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 193 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 194 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 195 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 196 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.5.4 REST OF LATIN AMERICA
    • TABLE 197 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 198 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 199 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 200 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 201 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 202 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
    • TABLE 203 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 204 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
    • TABLE 205 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 206 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 207 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 208 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 209 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.6.2 IMPACT OF ECONOMIC RECESSION ON MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • 13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
    • TABLE 210 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR DIAGNOSTIC MANUFACTURING COMPANIES
  • 13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 33 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
  • 13.4 MARKET SHARE ANALYSIS
    • FIGURE 34 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
    • TABLE 211 MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
    • 13.4.1 MOLECULAR DIAGNOSTICS MARKET SHARE AND RANKING ANALYSIS, BY TECHNOLOGY
      • 13.4.1.1 Polymerase chain reaction (PCR)
    • FIGURE 35 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE FOR PCR, BY KEY PLAYER (2022)
      • 13.4.1.2 DNA sequencing and NGS
    • FIGURE 36 GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE FOR DNA SEQUENCING & NGS, BY KEY PLAYER (2022)
      • 13.4.1.3 Isothermal nucleic acid amplification technology (INAAT)
    • TABLE 212 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INAAT, BY KEY PLAYER, 2022
      • 13.4.1.4 In situ hybridization (ISH)
    • TABLE 213 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR ISH, BY KEY PLAYER, 2022
    • 13.4.2 MOLECULAR DIAGNOSTICS MARKET RANKING ANALYSIS, BY APPLICATION
      • 13.4.2.1 Infectious diseases
    • TABLE 214 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INFECTIOUS DISEASES, BY KEY PLAYER, 2022
  • 13.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
    • 13.5.1 LIST OF EVALUATED VENDORS
    • 13.5.2 STARS
    • 13.5.3 EMERGING LEADERS
    • 13.5.4 PERVASIVE PLAYERS
    • 13.5.5 PARTICIPANTS
    • FIGURE 37 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
  • 13.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022)
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 STARTING BLOCKS
    • 13.6.3 RESPONSIVE COMPANIES
    • 13.6.4 DYNAMIC COMPANIES
    • FIGURE 38 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
  • 13.7 COMPETITIVE BENCHMARKING
    • 13.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS
    • FIGURE 39 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
    • TABLE 215 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
    • TABLE 216 COMPANY PRODUCT & SERVICE FOOTPRINT
    • TABLE 217 COMPANY REGIONAL FOOTPRINT
    • TABLE 218 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 13.8 COMPETITIVE SCENARIO
    • 13.8.1 KEY PRODUCT LAUNCHES
    • TABLE 219 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
    • 13.8.2 KEY DEALS
    • TABLE 220 KEY DEALS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 14.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 221 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • 14.1.2 HOLOGIC, INC.
    • TABLE 222 HOLOGIC, INC.: COMPANY OVERVIEW
    • FIGURE 41 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
    • 14.1.3 ABBOTT LABORATORIES
    • TABLE 223 ABBOTT LABORATORIES: COMPANY OVERVIEW
    • FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
    • 14.1.4 BIOMERIEUX
    • TABLE 224 BIOMERIEUX: COMPANY OVERVIEW
    • FIGURE 43 BIOMERIEUX: COMPANY SNAPSHOT (2022)
    • 14.1.5 THERMO FISHER SCIENTIFIC INC.
    • TABLE 225 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 14.1.6 QIAGEN
    • TABLE 226 QIAGEN: COMPANY OVERVIEW
    • FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2022)
    • 14.1.7 PERKINELMER INC.
    • TABLE 227 PERKINELMER INC.: COMPANY OVERVIEW
    • FIGURE 46 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
    • 14.1.8 MYRIAD GENETICS, INC.
    • TABLE 228 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
    • FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)
    • 14.1.9 SIEMENS HEALTHINEERS AG
    • TABLE 229 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
    • FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
    • 14.1.10 DANAHER
    • TABLE 230 DANAHER: COMPANY OVERVIEW
    • FIGURE 49 DANAHER: COMPANY SNAPSHOT (2022)
  • 14.2 OTHER PLAYERS
    • 14.2.1 ILLUMINA, INC.
    • 14.2.2 BECTON, DICKINSON AND COMPANY
    • 14.2.3 GRIFOLS, S.A.
    • 14.2.4 QUIDELORTHO CORPORATION
    • 14.2.5 AGILENT TECHNOLOGIES, INC.
    • 14.2.6 DIASORIN S.P.A.
    • 14.2.7 EXACT SCIENCES CORPORATION
    • 14.2.8 GENETIC SIGNATURES
    • 14.2.9 MDXHEALTH
    • 14.2.10 HTG MOLECULAR DIAGNOSTICS, INC.
    • 14.2.11 BIOCARTIS
    • 14.2.12 TBG DIAGNOSTICS LIMITED
    • TABLE 231 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
    • 14.2.13 VELA DIAGNOSTICS
    • TABLE 232 VELA DIAGNOSTICS: COMPANY OVERVIEW
    • 14.2.14 AMOY DIAGNOSTICS CO., LTD.
    • TABLE 233 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
    • 14.2.15 ELITECHGROUP
    • TABLE 234 ELITECHGROUP: COMPANY OVERVIEW
    • 14.2.16 MOLBIO DIAGNOSTICS PVT. LTD.
    • TABLE 235 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
    • 14.2.17 SAVYON DIAGNOSTICS
    • TABLE 236 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
    • 14.2.18 ABACUS DIAGNOSTICA OY
    • TABLE 237 ABACUS DIAGNOSTICA OY.: COMPANY OVERVIEW
    • 14.2.19 GENEOMBIO TECHNOLOGIES PVT. LTD.
    • TABLE 238 GENEOMBIO TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS